Researchers at Queen Mary University of London’s Precision Healthcare Research Institute (PHURI) and the Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin have identified the genetic causes of Raynaud’s phenomenon. Their findings, published today (12 October) in Nature Communications, could lead to the first effective treatments for people with Raynaud’s.
Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint – Pharmaceutical Technology
Transgene’s Phase II trial of viral-based vaccine TG4001 failed to meet its primary endpoint. Credit: Kitsawet Saethao via Shutterstock. Transgene’s stock has dropped after a
October 15, 2024